Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MenB and MenACWY Vaccines in Lab Workers
NCT00962624Phase 2Completed
- Start
- Jul 2010
- Primary completion
- Mar 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of meningococcal group B vaccine in meningococcal meningitis. Primary endpoint: Proportion of subjects attaining putative protective antibody concentrations against meningococci in the serum bactericidal antibody assay. Started Jul 2010; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT00962624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962624.